Harvard Bioscience, Inc. (OQ:HBIO)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 84 OCTOBER HILL RD
HOLLISTON MA 01746
Tel: N/A
Website: https://www.harvardbioscience.com
IR: See website
<
Key People
James W. Green
Chairman of the Board, President, Chief Executive Officer
Jennifer Cote
Chief Financial Officer, Treasurer
 
Business Overview
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
Financial Overview
For the fiscal year ended 31 December 2023, Harvard Bioscience, Inc. revenues decreased 1% to $112.3M. Net loss decreased 64% to $3.4M. Revenues reflect Instruments, equipment, software and accessories segment decrease of 2% to $105.7M, Rest of The World segment decrease of 22% to $12.8M, United States segment decrease of 3% to $48.2M. Lower net loss reflects Restructuring Charges & Provisions decrease of 78% to $320K (expense), Selling/General/Admin.
Employees: 391 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $216.29M as of Dec 31, 2023
Annual revenue (TTM): $112.25M as of Dec 31, 2023
EBITDA (TTM): $8.89M as of Dec 31, 2023
Net annual income (TTM): -$3.42M as of Dec 31, 2023
Free cash flow (TTM): $11.72M as of Dec 31, 2023
Net Debt Last Fiscal Year: $32.28M as of Dec 31, 2023
Shares outstanding: 43,399,291 as of Mar 1, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.